Reviewing Sage Therapeutics Inc. (SAGE)’s and Aptevo Therapeutics Inc. (NASDAQ:APVO)’s results

As Biotechnology companies, Sage Therapeutics Inc. (NASDAQ:SAGE) and Aptevo Therapeutics Inc. (NASDAQ:APVO) are our subject to compare. And more specifically their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sage Therapeutics Inc. 165 93.03 N/A -9.74 0.00
Aptevo Therapeutics Inc. 1 1.31 N/A -2.19 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Sage Therapeutics Inc. and Aptevo Therapeutics Inc.


Table 2 provides Sage Therapeutics Inc. and Aptevo Therapeutics Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Sage Therapeutics Inc. 0.00% -43.5% -40.6%
Aptevo Therapeutics Inc. 0.00% -122.3% -65.4%


Sage Therapeutics Inc.’s Current Ratio is 20.1 while its Quick Ratio is 20.1. On the competitive side is, Aptevo Therapeutics Inc. which has a 3.2 Current Ratio and a 2.9 Quick Ratio. Sage Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Aptevo Therapeutics Inc.

Analyst Recommendations

The table shown features the ratings and recommendations for Sage Therapeutics Inc. and Aptevo Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Sage Therapeutics Inc. 0 0 9 3.00
Aptevo Therapeutics Inc. 0 0 0 0.00

$212.67 is Sage Therapeutics Inc.’s consensus price target while its potential upside is 28.86%.

Insider and Institutional Ownership

Roughly 98.75% of Sage Therapeutics Inc. shares are held by institutional investors while 47% of Aptevo Therapeutics Inc. are owned by institutional investors. Insiders held roughly 1.2% of Sage Therapeutics Inc.’s shares. Insiders Competitively, held 4.5% of Aptevo Therapeutics Inc. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sage Therapeutics Inc. -8.19% -12.82% -3.85% 20.87% 6.31% 67.39%
Aptevo Therapeutics Inc. -3.58% 1.69% 26.24% -37.32% -79.73% -29.92%

For the past year Sage Therapeutics Inc. has 67.39% stronger performance while Aptevo Therapeutics Inc. has -29.92% weaker performance.


Sage Therapeutics Inc. beats on 7 of the 8 factors Aptevo Therapeutics Inc.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE), as well as for the treatment of post-partum depression (PPD). The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus. In addition, its product pipeline that are in preclinical stage comprises SAGE-105, a novel neuroactive steroid for the treatment of orphon epilepsies; SAGE-324, a novel neuroactive steroid for the treatment of GABA hypofunction; and SAGE-718, a novel oxysterol-based positive allosteric modulator of NMDA receptors for the treatment of cerebrosterol deficit disorders, anti-NMDA receptor encephalitis, and NMDA hypofunction. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. The companyÂ’s marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals. Its investigational stage product candidates include MOR209/ES414, a bispecific immunotherapeutic protein that is in Phase I clinical trial for metastatic castration-resistant prostate cancer; ES210, a bispecific protein therapeutic that is in pre-clinical development stage for inflammatory bowel diseases; otlertuzumab, a monospecific protein therapeutic that is in Phase II clinical trial for chronic lymphocytic leukemia; ROR1, a bispecific immunotherapeutic protein that is in preclinical development; APVO436, a bispecific protein therapeutic, which is in pre-clinical development; and other therapeutic protein product candidates for cancer. The company was incorporated in 2016 and is based in Seattle, Washington.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.